Key facts
- This page summarizes Ruth Alon's Form 4 filing for Silexion Therapeutics Corp (SLXN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Feb 2026, 16:20.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
No transaction description listed
Additional SEC filing notes
Footnote F1
The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's services as a director of the Issuer. The grant was approved by the Issuer's board of directors.
Footnote F2
The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, in respect of the Reporting Person's services as a director of the Issuer, which grant was approved by the Issuer's board of directors.
Footnote F3
The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
Footnote F4
There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.